What are the therapeutic needs in schizophrenia and how are they satisfied by new antipsychotics?

International Clinical Psychopharmacology

Volumn 12, Issue SUPPL. 2, 1997, Pages

  Kane, John M ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Adverse effects; Antipsychotics; Maintenance treatment; Negative symptoms

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOZAPINE; FLUPHENAZINE; NEUROLEPTIC AGENT;

AGRANULOCYTOSIS; CONFERENCE PAPER; DOPAMINERGIC TRANSMISSION; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE NEED; HUMAN; MAINTENANCE THERAPY; NEGATIVE SYNDROME; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEIZURE; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; HUMANS; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0030752922     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199705002-00002     Document Type: Conference Paper

References (28)

1. Addington DE, Toewes JA, Addington JM (1995) Risperidone and tardive dyskinesia. J Clin Psychiatry 56:484-485.
2. Alvir JM, Lieberman JA, Safferman AZ, et al. (1993) Clozapineinduced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 329: 162-167.
3. Bondolfi G, Baumann P, Patris M, et al. (1995) A randomized double-blind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia. Eur Neuropsychopharmacol 5:349.
4. Breier A, Buchanan RW, Kirkpatrick B, et al. (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 51:20-26.
5. Carpenter WT Jr, Conley RR, Buchanan RW, et al. (1995) Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 152:827-832.
6. Christison GW, Kirch DG, Wyatt RJ (1991) When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 17:217-245.
7. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483.
8. Devinsky O. Pacia SV (1994) Seizures during clozapine therapy. J Clin Psychiatry 55 (suppl B): 153-156.
9. Devinsky O, Honigfeld G, Patten J (1991) Clozapine-related seizures. Neurology 41:369-371.
10. Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr (1993) Principles and Practice of Pharmacotherapy. Baltimore: Williams and Wilkins.
11. Jeste DV. Caligiuri MP (1993) Tardive dyskinesia. Schizophr Bull 19:303-315.
12. Kane JM (1996a) A six-month comparison of clozapine and haloperidol [abstract]. In: 35th American College of Neuropsychopharmacology Annual Meeting, San Juan, Puerto Rico, December 9-13. Nashville, Tennessee: American College of Neuropsychopharmacology; p 65.
13. Kane JM (1996b) Who shall decide when doctors disagree? [editorial comment]. Am J Psychiatry 153:1507-1508.
14. Kane J, Mayerhoff D (1989) Do negative symptoms respond to pharmacologic treatment? Br J Psychiatry 55 (suppl 7): 115-118.
15. Kane JM, Woerner M, Sarantakos S (1986) Depot neuroleptics: a comparative review of standard, intermediate and low dose regimens. J Clin Psychiatry 47 (suppl 5):30-33.
16. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/benztropine. Arch Gen Psychiatry 45: 789-796.
17. Kane JM, Safferman AZ, Pollack S, et al. (1993) Clozapine. negative symptoms and extrapyramidal side effects. J Clin Psychiatry 55 (suppl B):48-74.
18. Kinon BJ, Kane JM, Johns C, et al. (1993) Treatment of neuroleptic resistant schizophrenic relapse. Psychopharmacol Bull 29:309-314.
19. Klein DF, Davis JM (1969) Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore: Williams and Wilkins.
20. Levinson DF, Simpson GM, Singh H, et al. (1990) Fluphenazine dose, clinical response and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 47:761-768.
21. Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835.
22. Meltzer HY (1995) Clozapine: is another view valid? Am J Psychiatry 52:821-825.
23. NIMH Psychopharmacology Service Center Collaborative Study Group (1964) Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 10:246-261.
24. Rifkin A, Doddi S, Karagi B, et al. (1991) Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 48:166-170.
25. Saltz BL, Woerner MG, Kane JM, et al. (1991) Prospective study of tardive dyskinesia incidence in the elderly. JAMA 266:2402-2406.
26. Van Putten T, Marder SR, Mintz J (1990) A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 47:754-758.
27. Volavka J, Cooper T, Czobor P, et al. (1992) Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 49:354-361.
28. Woerner MG, Lieberman JA, Kane JM, Sheitman BB (1996) Risperidone-induced tardive dyskinesia: a case report. Am J Psychiatry 153:843.